瑞豐高材(300243.SZ):全資子公司取得1項實用新型專利證書
格隆匯5月25日丨瑞豐高材(300243.SZ)公佈,公司全資子公司臨沂瑞豐高分子材料有限公司(“臨沂瑞豐”)申請的1項實用新型專利於近日獲得國家知識產權局頒發的實用新型專利證書,涉一種酸相法生產氯化聚乙烯用脱酸壓濾裝置。
該專利涉及一種酸相法生產氯化聚乙烯用脱酸壓濾裝置,屬於化工生產設備技術領域,可提高生產效率,減少工藝水的用量和低濃度酸的產生,同時降低了能耗。
上述專利證書的取得和應用不會對公司及臨沂瑞豐近期生產經營產生重大影響,但有利於充分發揮公司自主知識產權優勢,有利於公司的技術創新,從而提升公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.